2024-08-08 14:54:37
Health authorities have warned of difficulties supplying the Anapen pen.
The U.S. National Drug Safety Administration (ANSM) reported on Thursday, August 8, a tight supply situation for the Anapen epinephrine injection pen, which is “planned to be generally available in the first quarter of 2025.”
“All three doses are affected”: Anapen 300 microgram (μg) pens are “currently” out of stock, and “from September, the 150 μg and 500 μg pens will also be out of stock,” ANSM warns on its website. website.
another brand specified
These auto-injector pens are indicated for the emergency treatment of symptoms of anaphylactic shock, which can be fatal and constitute an absolute medical emergency.
According to the National Institute of Health and Medicine (Inserm), the most common allergens that cause anaphylactic shock are foods (such as peanuts, pistachios, shellfish, eggs, etc.), wasp, bee or bumblebee venom, medications, and latex .
Pollen: Why are more and more people allergic?
The medical policeman pointed out that “this rupture was not due to a quality defect” but rather due to “a shift in the production location that resulted in a delay in the supply of Anapen pens marketed by Bioprojet Laboratories”.
“To compensate for these temporary disruptions, patients receiving Anapen will have another brand of epinephrine auto-injector pen, either Epipen or Jext, at their next consultation,” ANSM stressed.
Difficulties in supplying epinephrine auto-injectors frequently arise.
1723173296
#supply #epinephrine #pens #tight #expected #return #normal
